确定氟达拉滨最佳暴露量以改善侵袭性B细胞非霍奇金淋巴瘤患者接受阿基仑赛治疗后的结局
研究利用多中心 consortium 数据,在199例接受商业化阿基仑赛(Axi-cel)的侵袭性B细胞非霍奇金淋巴瘤成人患者中,用群体药代动力学模型估算氟达拉滨暴露量(AUC),分析其与疗效及耐受性的关联。结果显示AUC 18-20 mgh/L组6个月复发/进展累积发生率28%、1年PFS 66%、OS 77%,优于低AUC组和高AUC组;高AUC组任何级别ICANS风险最高。作者认为通过药代动力学指导氟达拉滨给药以达到最佳AUC可能改善接受Axi-cel患者的结局。
要点
- 氟达拉滨AUC 18-20 mgh/L组6个月复发/进展累积发生率28%,低AUC组54%,高AUC组30%。
- 最佳AUC组1年PFS 66%、OS 77%,低AUC组分别为39%和58%,高AUC组分别为46%和66%。
- 高AUC组任何级别ICANS风险最高(HR 1.9),且非复发死亡包括3例ICANS死亡更常见。
核心结论
- 药代动力学指导氟达拉滨给药以达到最佳AUC可能改善接受阿基仑赛患者的结局。
研究设计与样本
- 多中心 consortium 研究,纳入199例接受商业化阿基仑赛的侵袭性B细胞非霍奇金淋巴瘤成人患者,用群体药代动力学模型估算氟达拉滨AUC。
主要发现
- 按氟达拉滨AUC分为低(<18 mgh/L)、最佳(18-20 mgh/L)和高(>20 mgh/L)三组。
- 6个月复发/进展累积发生率:低AUC组54%(45%-62%),最佳AUC组28%(15%-44%),高AUC组30%(14%-47%)。
- 1年PFS率:低AUC组39%(31%-48%),最佳AUC组66%(52%-84%),高AUC组46%(30%-70%)。
- 1年OS率:低AUC组58%(50%-67%),最佳AUC组77%(64%-92%),高AUC组66%(50%-87%)。
临床怎么用
- 作者认为通过药代动力学指导氟达拉滨给药以达到最佳AUC可能改善接受阿基仑赛患者的结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fludarabine is one of the most common agents given for lymphodepletion before CD19 chimeric antigen receptor T cells, but its optimal therapeutic intensity is unknown. Using data from a multicenter consortium, we estimated fludarabine exposure (area under the curve [AUC]) using a population pharmacokinetic (PK) model in 199 adult patients with aggressive B-cell non-Hodgkin lymphomas who received commercial axicabtagene ciloleucel (Axi-cel). We evaluated the association of estimated fludarabine AUC with key outcomes, aiming to find an AUC that optimized efficacy and tolerability. We identified low (<18 mg × hour/L [mgh/L]), optimal (18-20 mgh/L), and high (>20 mgh/L) AUC groups for analyses; the 6-month cumulative incidences of relapse/progression of disease (relapse/POD) by AUC groups were 54% (45%-62%), 28% (15%-44%), and 30% (14%-47%), respectively; and the 1-year progression-free survival (PFS) rates were 39% (31%-48%), 66% (52%-84%), and 46% (30%-70%) and the overall survival (OS) rates were 58% (50%-67%), 77% (64%-92%), and 66% (50%-87%), respectively. In multivariable analyses compared with low AUC, an optimal AUC was associated with the highest PFS (hazard ratio [HR], 0.52; 0.3-0.91; P = .02) and lowest risk of relapse/POD (HR, 0.46; 0.25-0.84; P = .01) without an increased risk of any-grade cytokine release syndrome (HR, 1.1; 0.7-1.6; P = .8) or and immune effector cell-associated neurotoxicity syndrome (ICANS) (HR, 1.36; 0.83-2.3; P = .2). A high AUC was associated with the greatest risk of any-grade ICANS (HR, 1.9; 1.1-3.2; P = .02). Although the main cause of death in all groups was relapse/POD, nonrelapse-related deaths, including 3 deaths from ICANS, were more frequent in the high AUC group. These findings suggest that PK-directed fludarabine dosing to achieve an optimal AUC may result in improved outcomes for patients receiving axi-cel.
引用
- Scordo M, Flynn JR, Gonen M, et al. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. Blood Adv. 2023. PMID: 37522731. doi:10.1182/bloodadvances.2023010302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。